Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Stem cells injected into eyes: a new hope for blindness?

NCT ID NCT01736059

Disease control Sponsor: University of California, Davis Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing whether it is safe to inject a person's own bone marrow stem cells into their eye to treat vision loss from conditions like macular degeneration and diabetic retinopathy. Fifteen adults with severe vision loss will receive the injection and be monitored for side effects. The goal is to check safety and feasibility, not yet to see if it improves eyesight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CD34+ bone marrow stem cells
What this could lead to
If safe, this could pave the way for larger studies exploring stem cell injections as a treatment for certain types of vision loss.
What could go wrong
This is a very early, small safety trial with only 15 people. It is not designed to prove the treatment works, and there are risks like infection or vision loss from the injection itself.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 15 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Jul 2012

Expected to finish

Oct 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * age \>18 years of age * visual acuity 20/100 to CF * duration of vision loss \> 3 months * vision loss from macular degeneration, retinitis pigmentosa, retinal vein occlusion or diabetic retinopathy * the study eye has the worse visual acuity * no active eye or systemic disease * no history of macular edema or retinal/choroidal neovascularization requiring treatment within 6 months * no significant media opacity * no coagulopathy or other hematologic abnormality * no concurrent immunosuppressive therapy * able to keep follow-up for 6 months Exclusion Criteria: * allergy to fluorescein dye * other concurrent retinal or optic nerve disease affecting vision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetic retinopathy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetic retinopathy dry age related macular degeneration hereditary macular dystrophy retinal disorder retinal vein occlusion retinitis pigmentosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetic retinopathy Hereditary macular degeneration Non-exudative age-related macular degeneration Retina vein occlusion Retinitis pigmentosa

Contacts and locations

Locations

  • University of California Davis

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.